Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda(Brigham and Women's Hospital), J. Hans DeVries(Amsterdam UMC Location University of Amsterdam), Ludger Rose(German Center for Diabetes Research), Stephen C. Bain(Swansea University), Everton Rowe(Novo Nordisk (United States)), Bertrand Cariou(Institut du Thorax), Mads Axelsen(Novo Nordisk (Denmark)), Milivoj Piletič(School of Business and Management Novo Mesto)
The Lancet Diabetes & Endocrinology
March 24, 2017
10.1016/s2213-8587(17)30085-2
Cited by 439

Related Papers

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
International Consensus on Use of Continuous Glucose Monitoring
|Diabetes Care|2017|2k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986